drugset / Trial / NCT04167813
Trial of Ondansetron as a Parkinson's HAllucinations Treatment
Phase 2
Unknown
168 enrolled
University College, London
Custom Pharmaceuticals Limited · collabMODEPHARMA Limited · collabPRIMENT · collabParkinson's UK · collabSEALED ENVELOPE · collabWasdell Packaging Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
TOPHAT (Trial of Ondansetron as a Parkinson's HAllucinations Treatment) is a double blind, individually randomized, placebo-controlled, parallel group, flexible dose trial of ondansetron (8-24mg/day) as a treatment for Parkinson's hallucinations, with a 12-week primary outcome and follow-up to 24 weeks.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ondansetron | Other / unclassified | 24 mg | — |